For business
Science & DTx
About us
Contact us

Stephen Bruso

The Board

Stephen Bruso joined the Morningside investment team in 2019 and focuses on investments in both the biopharma and digital health fields. He has extensive experience providing operational and management oversight to early-stage companies. Mr. Bruso serves as a director for numerous private companies including Cognito Therapeutics, Curai, Suvera, Vesigen Therapeutics, Neuroelectrics, Innodem Neurosciences, Manistee Therapeutics, MedRhythms, Huckleberry, Ieso Digital Health, Wellinks, and DeepCure; he is a board observer at Linus Health.

Prior to joining Morningside, Mr. Bruso worked at a series of molecular diagnostics startups spun out from the Church Lab at HMS before co-leading the development and launch of cloud software products at an e-commerce startup. He received his MBA from Boston University in 2019, graduating magna cum laude. He received hisBA from Emory University in 2009.

Dr Andy Blackwell

Group Chief Science & Strategy Officer

Kate Woolland

Chief Delivery Officer

Dr Valentin Tablan

Chief Artificial Intelligence Officer

Danah Tangen

Chief of Staff

James Kellerman

Chief Technology Officer

Dr Charlotte Housden

Chief Operating Officer

Lynn Lakey

Interim Managing Director

Chris Kightley

Interim Managing Director

Dr Andrew Welchman

EVP for Impact

Dr Jennifer Gentile

SVP Clinical Innovation

Stephen Freer

EVP Clinical

Clare Hurley

EVP Clinical